It is conceivable that testing tumours for TM4SF expression, in combination with other molecular and biochemical assays, may improve the prognostic evaluation of colon cancer patients, and enhance the clinician's ability to prospectively identify patients who will have early disease recurrence and who require adjuvant chemotherapy. The gene discussed is TSPAN1; the disease is neoplasm.